Introduction {#sec1_1}
============

Acute myeloid leukemia (AML) with the t(8; 22) (p11; q13) translocation is a rare subtype of AML. t(8; 22) (p11; q13) is a novel chromosomal translocation whose function has not been fully elucidated. The oncogenesis of AML with the t(8; 22) (p11; q13) translocation was demonstrated to be caused by the fusion protein monocytic leukemia zinc finger protein (MOZ) and transcription factor p300 \[[@B1]\]. MOZ encodes a potential histone acetyltransferase and was identified as the gene that is located at the breakpoint of t(8; 16). The chromosomal translocation t(8; 16) has been found in AML \[[@B2]\], and it is one of the most common causes of aberrant cytogenesis in AML. MOZ can be fused to various translocation targets including CBT, TIF2, and p300, corresponding to t(8; 16), inv(8), and t(8; 22), respectively. Indeed, t(8; 22) is a novel chromosomal translocation \[[@B3], [@B4]\], and the leukemogenesis has been investigated only over the past decade.

Case Report {#sec1_2}
===========

An 80-year-old Japanese male was diagnosed with therapy-related myelodysplastic syndrome (MDS) 9 months after chemotherapy for non-Hodgkin lymphoma. An unrecovered anemia was detected after chemotherapy. His bone marrow revealed a substantial degree of sea-blue histiocytosis at 1.0%.

After several months of follow-up, his white blood cell count increased up to 52.73 × 10^3^/µL with 16.0% of immature myeloid cells. He underwent bone marrow aspiration. He was then diagnosed with AML, M4 according to the FAB classification along with myelodysplastic/myeloproliferative neoplasm (MDS/MPN)-type marrow proliferative disease (Fig. [1a, b](#F1){ref-type="fig"}). His karyotype revealed translocation between chromosomes 8p11 and 22q13, which is a rare translocation with a prevalence of less than 1.0% among all AML cases \[[@B3], [@B4]\]. The patient received chemotherapy consisting of low-dose cytarabine 20 mg/kg body weight for 10 days, but eventually died of the disease.

Discussion {#sec1_3}
==========

Erythro- or hemophagocytosis by blasts is the hallmark of leukemia associated with t(8:16) and was noted to various degrees in most of the patients (22 out of 24) examined by Stark et al. \[[@B5]\]. This subgroup of AML reveals other hallmarks of the disease, including monocytic arrest and erythrophagocytosis \[[@B6]\]. These morphological features are sometimes observed as various degrees of phagocytosis-associated monograms including erythrophagocytosis \[[@B5]\] that represent aberrant biological behavior. Although erythro-/hemophagocytosis was limited in our AML patient, a remarkable degree of sea-blue histiocytosis was found in his bone marrow (Fig. [1c, d](#F1){ref-type="fig"}). Sea-blue histiocytes are macrophages harboring blue vacuoles and granular deposition, which is caused by the phagocytosis of increased numbers of dead cells and the subsequent deposition of phospholipids \[[@B7]\]. Sea-blue histiocytosis has been reported to be associated with chronic myeloid leukemia \[[@B8]\], MDS \[[@B9]\] and lymphoma \[[@B10]\]. However, as the previous report describes, a substantial proportion of the AML M4/M5 subtype harboring MOZ as an aberrant fusion gene represent erythrophagocytosis \[[@B5]\]. Although rare, t(8; 22) is very specific to the AML M4/M5 subtype \[[@B1]\]. We speculate that as in many cases of classical monocytic leukemia, sea-blue histiocytosis should be added as one of the characteristic features of monocytic AML with macrophage activation in AMLs with genetic abnormalities including t(8; 22).
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